Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Would you defer or opt for plavix loading during PCI in a patient already on DAPT presenting with NSTEMI attributed to non-ischemic myocardial injury but with known CAD?
Related Questions
How do you approach revascularization in patients over 75 years with NSTEMI, given recent evidence from the SENIOR-RITA trial that an invasive strategy does not significantly reduce cardiovascular events compared to a conservative strategy?
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
What has been your experience with Coronary CTA with FFR results and its ability to accurately predict epicardial CAD on diagnostic LHC?
What are your preferred femoral vascular closure devices for severely calcified femoral artery vessels following PCI, especially with higher sticks, and why?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
What advice would you give to patients with refractory nausea and vomiting at home who are unable to take oral medications but have recently had a PCI and stent placement requiring uninterrupted DAPT?
Do you prefer the routine use of bivalirudin over UFH during PCI cases in patients presenting with ACS?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
What is your antiplatelet and anticoagulant approach in a patient with likely Type 1 NSTEMI and history of Afib awaiting LHC?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
